Andere Sprachen C4 Therapeutics, Inc.

Aktien

A2QC0X

US12529R1077

CCCC

Realtime-Estimate Cboe BZX Andere Börsenplätze 16:43:49 06.06.2024			% 5 Tage	% 1. Jan.
4,77 ^USD	-3,64 %		-3,31 %	-14,78 %

09.05.	C4 THERAPEUTICS, INC. : Bewertung von Stifel Nicolaus kaufen	ZM
08.05.	C4 Therapeutics-Aktien fallen, da Q1-Umsatz die Schätzungen verfehlt	MT

Andere Sprachen

Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!

100% kostenlose Registrierung

C4 Therapeutics Shares Decline as Q1 Revenue Misses Estimates	08.05.
C4 Therapeutics : Corporate Presentation – May 2024	08.05.
C4 Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	08.05.
C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights	08.05.
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	29.04.
C4 Therapeutics to Participate in the Stifel 2024 Targeted Oncology Forum	09.04.
C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024	08.04.
C4 Therapeutics, Inc. Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024	08.04.
C4 Therapeutics, Inc.(NasdaqGS:CCCC) added to S&P Biotechnology Select Industry Index	18.03.
C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC Degraders at the American Association for Cancer Research Annual Meeting 2024	06.03.
C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC™ Degraders at the American Association for Cancer Research Annual Meeting 2024	05.03.
C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC™ Degraders at the American Association for Cancer Research Annual Meeting 2024	05.03.
C4 Therapeutics Collaborating With Germany's Merck KGaA to Advance Research on Targeted Therapies for Cancer	04.03.
C4 Therapeutics : Corporate Presentation – March 2024	04.03.
C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins	04.03.
C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins	04.03.
C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA Against Critical Oncogenic Proteins	04.03.
C4 Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	22.02.
C4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights	22.02.
North American Morning Briefing : Stock Futures -2-	21.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen C4 Therapeutics, Inc.

Aktien

A2QC0X

US12529R1077

CCCC

Andere Sprachen

Filter